FDA Grants Orphan Drug Status for CF102 for the Treatment of Hepatocellular Carcinoma to Can-Fite BioPharma

PETAH-TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Status for its drug candidate, CF102, for the treatment of hepatocellular carcinoma

Feed Date: 
February 23, 2012